CompletedPhase 2/3

Pirfenidone LP or Collagen-polyvinylpyrrolidone in COVID-19

Mexico36 participantsStarted 2020-02-01

Plain-language summary

Collagen-polyvinylpyrrolidone (collagen-PVP) and pirfenidone have the ability to control cytokine storms. This work explores the therapeutic effects of both, on the early treatment of patients with severe COVID-19. The hospital stay, quick COVID-19 severity index (qCSI) and admission to the ICU were statistically significantly lower when the patients were treated with collagen-PVP or pirfenidone, compared to the controls treated with dexamethasone alone.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients infected with SARS-CoV-2, hospitalized, with total bilirubin ≤1.5 Exclusion Criteria: * if the patient underwent treatment with biological antirheumatic drugs, disease modifiers (DMARDs) or other immunosuppressive agents, patients who required continuous therapy with systemic corticosteroids in a dose greater than 10 mg of prednisone per day or equivalent; pregnant women, calculated creatinine clearance (or estimated glomerular filtration rate less than 10 ml/min or patients requiring renal replacement therapy

What they're measuring

Number of patients that survived the COVID-19 infection

Timeframe: From enrollment until one month of follow up

Trial details

NCT IDNCT06585319

SponsorMaterno-Perinatal Hospital of the State of Mexico

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-06-30

View on ClinicalTrials.gov More COVID 19 trials